Skip to main content

Table 2 Efficacy of treatment in the XELIRI and FOLFIRI arms (response rate, R0 resection* rate), data are shown as n (%)

From: Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial

 

XELIRI

FOLFIRI

 
 

n = 41

n = 46

p

Complete response

5 (12%)

1 (2%)

0.10

Partial response

15 (37%)

21 (46%)

0.32

Objective response

20 (49%)

22 (48%)

0.76

Stagnation

12 (29%)

10 (22%)

0.67

Progressive disease

7 (17%)

11 (24%)

0.35

R0 resection*

10 (24%)

11 (24%)

0.83

Complete response + R0 resection

15 (37%)

12 (26%)

0.56

  1. R0 resection* – > 10 mm tumour-free resection margin on histology